Lilly presents new Emgality data
May 2, 2019Eli Lilly will present 19 scientific abstracts for headache preventive drug Emgality (galcanezumab-gnlm) and lasmiditan at the 71st Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia from May 4-10, 2019.
Emgality (120 mg) is indicated for the preventive treatment of migraine, Emgality (300 mg) is an investigational drug for the preventive treatment of episodic cluster headache, and lasmiditan is an investigational drug for the acute treatment of migraine, all in adults.
Gudarz Davar, M.D., vice president, Neurology Development, Lilly Bio-Medicines, said that the data presented at AAN reflect Lilly’s deep commitment and expertise in searching for and finding solutions for some of today’s toughest challenges in migraine and disabling headache disorders.
In a plenary session on May 7, 2019, Lilly will highlight Phase 3, eight-week findings for Emgality as an investigational preventive treatment for episodic cluster headache in adults. On May 6, 2019, Lilly will also present analyses from two Phase 3 studies (EVOLVE-1 & EVOLVE-2) evaluating Emgality in a subgroup of adults living with episodic migraine, by low- versus high-frequency of migraine headache days.
Lilly will also share new data for lasmiditan, including details on the onset of efficacy, in a platform presentation on May 6, 2019, and in a poster presentation based on clinical data from the Phase 3 GLADIATOR long-term extension study. Lasmiditan is an oral, centrally-penetrant, selective serotonin 5-HT1F agonist that is structurally and mechanistically distinct from other approved migraine therapies and lacks vasoconstrictive activity. It is the first and only molecule in the “-ditan” class under evaluation by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults. If approved, it could represent the first significant innovation for the acute pharmacological treatment of migraine in more than two decades.
